News | January 31, 2026
Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
India Business grew by 11.9% YoY to Rs. 1196.2 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Key takeaways of Q3FY22 quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
